Summit Therapeutics Inc (NASDAQ: SMMT) has seen a rise in its stock price by 3574057 in relation to its previous close of 20.39. However, the company has experienced a 4.86% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
SMMT has 36-month beta value of -1.05. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SMMT is 111.44M, and currently, short sellers hold a 21.93% ratio of that float. The average trading volume of SMMT on June 25, 2025 was 4.77M shares.
SMMT’s Market Performance
The stock of Summit Therapeutics Inc (SMMT) has seen a 4.86% increase in the past week, with a -18.82% drop in the past month, and a 1.11% gain in the past quarter. The volatility ratio for the week is 1.49%, and the volatility levels for the past 30 days are at 9.70% for SMMT. The simple moving average for the past 20 days is -0.22% for SMMT’s stock, with a -0.01% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Leerink Partners repeating the rating for SMMT by listing it as a “Underperform.” The predicted price for SMMT in the upcoming period, according to Leerink Partners is $12 based on the research report published on June 11, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see SMMT reach a price target of $35, previously predicting the price at $23. The rating they have provided for SMMT stocks is “Buy” according to the report published on March 26th, 2025.
SMMT Trading at -11.47% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.32% of loss for the given period.
Stock Fundamentals for SMMT
The total capital return value is set at -0.48. Equity return is now at value -123.93, with -85.89 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -26.84. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -30.27.
Currently, EBITDA for the company is -212.85 million with net debt to EBITDA at 1.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.63.
Conclusion
To put it simply, Summit Therapeutics Inc (SMMT) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
